Janux Therapeutics, Inc.
Financials
Valuation Metrics
Janux Therapeutics, Inc.'s Market Cap is $1.03B. At end of 2025 it was $855M. Ranked #2459 of 3,121 in US market (top 79%), #1008 of 1,463 on NASDAQ (top 69%), #187 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.03B | US#2,459/3,121 Sec#187/266 |
| Net Income | $-103M | US—/3,121 Sec—/266 |
| Total Assets | $1.01B | US#2,476/3,121 Sec#103/266 |
| Net Assets | $928M | US#1,815/3,121 Sec#70/266 |
| Employees | 113 | US#2,603/3,121 Sec#168/266 |
| Value | ||
| P/B | 1.11x | US#484/3,121 Sec#16/266 |
| P/S | 102.82x | US#2,948/3,121 Sec#178/266 |
| FCF Yield | -5.30% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -11.06% | US#2,381/3,121 Sec#82/266 |
| ROA | -10.18% | US#2,665/3,121 Sec#102/266 |
| Financial Health | ||
| Debt Ratio | 8.59% | US#88/3,121 Sec#41/266 |
| Total Debt | $21M | US#2,752/3,121 Sec#188/266 |
| FCF | $-55M | US#2,533/3,121 Sec#115/266 |
| Cash | $28M | US#2,781/3,121 Sec#248/266 |
| Current Ratio | 16.35x | US#149/3,121 Sec#41/266 |
| Performance | ||
| 1Y Return | -28.13% | US#2,584/3,121 Sec#223/266 |
| 1M Return | -0.59% | US#1,026/3,121 Sec#99/266 |
| From 52W High | -52.29% | US#2,782/3,121 Sec#220/266 |
| 1Y MDD | -64.94% | US#2,884/3,121 Sec#229/266 |
| Trading | ||
| Volume | 773,700 shares | US#1,632/3,121 Sec#175/266 |
| Trading Value | $13M | US#2,183/3,121 Sec#178/266 |
| Per Share | ||
| EPS | $-1.68 | US—/3,121 Sec—/266 |
| BPS | $15.22 | US#1,519/3,121 Sec#47/266 |
Company Info
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.